While mindful of a liability risk, we continue to believe this company’s exposure will be minimal, if anything.
Source
We’re using a pullback in one of our drug stocks to buy more shares
Health
Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise
Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed. Shares of Eli Lilly entered Wednesday’s session off nearly 9% since the Oct. 30 close, the day that the drugmaker’s messy third-quarter earnings report sent the stock down 6%. Zoom out further to […]
Read More
Health
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The U.S. Food and […]
Read More
Health
Private equity reduces patient care while enriching investors, Senate report finds
A year-long bipartisan Congressional investigation into two private equity-backed U.S. hospital systems found that patient care deteriorated at both operations as their private equity owners reaped significant payouts on their investments in the systems. The findings reinforced academic research showing how private equity healthcare investments harm patients while enriching investors. The investigation was helmed by two senators […]
Read More